Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Receivables (2022 - 2025)

Historic Receivables for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $2.2 million.

  • Coeptis Therapeutics Holdings' Receivables changed N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $38978.0 for FY2023, which is 38269.97% up from last year.
  • Coeptis Therapeutics Holdings' Receivables amounted to $2.2 million in Q3 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Receivables ranged from a high of $2.2 million in Q3 2025 and a low of $833.0 during Q3 2023
  • For the 4-year period, Coeptis Therapeutics Holdings' Receivables averaged around $404462.9, with its median value being $38978.0 (2023).
  • Data for Coeptis Therapeutics Holdings' Receivables shows a peak YoY increase of 38269.97% (in 2023) and a maximum YoY decrease of 38269.97% (in 2023) over the last 5 years.
  • Coeptis Therapeutics Holdings' Receivables (Quarter) stood at $8075.0 in 2022, then soared by 382.7% to $38978.0 in 2023, then surged by 178.57% to $108581.0 in 2024, then surged by 1910.36% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $30000.0 for Q2 2025, and $108581.0 during Q1 2024.